Taxol NSCLC Survival Data Are Consistent With FDA Panel's Expectations
Executive Summary
Members of FDA's Oncologic Drugs Advisory Committee were convinced that Bristol-Myers Squibb's Taxol (paclitaxel) showed a survival benefit in non-small cell lung cancer despite an FDA analysis that did not find a statistically significant difference from the comparator regimen.